Cipla expects to commence supplies to US from China plant later this year

Cipla plans to start supplying from its China facility to the US market by the second half of the current fiscal year, following USFDA approval. The company is resolving regulatory issues with its domestic plants and focusing on new therapeutic areas and tech-based solutions. Cipla is also addressing antimicrobial resistance and expanding its digital health initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pvuqdyt
via IFTTT